Beam Therapeutics BEAM EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Beam Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's EBITDA margin?
- Beam Therapeutics (BEAM) reported EBITDA margin of -212.9% in Q1 2026.
- How has Beam Therapeutics's EBITDA margin changed year-over-year?
- Beam Therapeutics's EBITDA margin increased by 66.9% year-over-year, from -642.8% to -212.9%.
- What is the long-term trend for Beam Therapeutics's EBITDA margin?
- Over 4 years (2020 to 2025), Beam Therapeutics's EBITDA margin has grown at a -85.2% compound annual growth rate (CAGR), from -533,437.5% to -258.6%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.